XML 32 R14.htm IDEA: XBRL DOCUMENT
v3.6.0.2

SHARE CAPITAL | 12 Months Ended
--- | ---
Dec. 31, 2016
SHARE CAPITAL [Abstract] |
SHARE CAPITAL | NOTE 7 - SHARE CAPITAL
| a. | Rights of the Company’s Common Stock
The Company’s Common Stock is listed on the NYSE MKT and on the Tel Aviv Stock Exchange. Each share of Common Stock is entitled to one vote. The holders of shares of Common Stock are also entitled to receive dividends whenever funds are legally available, when and if declared by the Board of Directors. Since its inception, the Company has not declared any dividends.
| b. | Stock based compensation
On December 14, 2006, the Board of Directors adopted the Protalix BioTherapeutics, Inc. 2006 Stock Incentive Plan, as amended (the “Plan”). The Plan has since been amended to, among other things, increase the number of shares of common stock available under the plan to 13,841,655 shares. The grant of options to Israeli employees under the Plan is subject to the terms stipulated by Sections 102 and 102A of the Israeli Income Tax Ordinance. Each option grant is subject to the track chosen by the Company, either Section 102 or Section 102A of the Israeli Income Tax Ordinance, and pursuant to the terms thereof, the Company is not allowed to claim, as an expense for tax purposes, the amounts credited to employees as a benefit, including amounts recorded as salary benefits in the Company’s accounts, in respect of options granted to employees under the Plan, with the exception of the work-income benefit component, if any, determined on the grant date. For Israeli non-employees, the share option plan is subject to Section 3(i) of the Israeli Income Tax Ordinance. As of December 31, 2016, 2,391,481 shares of Common Stock remain available for grant under the Plan. For purposes of determining the fair value of the options and restricted stock granted to employees and non-employees, the Company’s management uses the fair value of the Common Stock. From January 1, 2014 through December 31, 2016, the Company granted options and shares of restricted stock to certain employees and non-employees as follows:
| 1. | Options and restricted stock granted to employees:
| a) | Below is a table summarizing all of the options and restricted stock grants to employees for each year of the two-year period ended December 31, 2015:
|  |  |  |  |  |  | Fair value |  |
|  |  |  |  |  |  | at grant |  |
|  |  |  |  |  |  | (U.S. |  |
Year of |  | No. of options |  | Exercise |  |  | dollars in |  | Expiration |
grant |  | granted |  | price |  | Vesting period |  | thousands) |  | period |
2014 |  |  | 900,000 |  | $ | 2.37 |  |  | 4 years |  | $ | 1,007 |  |  | 10 years |
2015 |  |  | 1,909,000 |  | $ | 1.72 |  |  | 4 years |  | $ | 1,900 |  |  | 10 years |
|  |  | 2,809,000 |  |  |  |  |  |  |  |  |  |  |  |  |
Set forth below are grants made by the Company to employees (including related parties) during the three-year period ended December 31, 2016 (such grants appear in the table above): On September 28, 2014, the Company’s Board of Directors approved, subject to certain terms and conditions, the grant of a 10-year option to purchase 900,000 shares of Common Stock to its then newly appointed President and Chief Executive Officer with an exercise price of $2.37 per share. The options vest over a four-year period in 16 equal quarterly increments. Vesting of the options will be accelerated in full upon a Corporate Transaction or a Change in Control, as those terms are defined in the Plan, as amended. The Company estimated the fair value of the options on the date of grant, using the Black-Scholes option-pricing model, to be approximately $1.0 million based on the following weighted average assumptions: dividend yield of 0% for all years; expected volatility of 62%; risk-free interest rate of 1.86%; and expected life of six years. On March 23, 2015, the Company’s compensation committee approved the grant of a 10-year option to purchase 1,909,000 shares of Common Stock to its officers and other employees with an exercise price equal to $1.72 per share under the Plan. The options vest over a four-year period; the first 25% shares vest on the first anniversary of the grant date and the remaining shares vest in 12 equal quarterly increments over the subsequent three-year period. Vesting of the options granted to certain executive officers is subject to acceleration in full upon a Corporate Transaction or a Change in Control, as those terms are defined in the Plan. The Company estimated the fair value of the options on the date of grant using the Black-Scholes option-pricing model to be approximately $1.9 million based on the following weighted average assumptions: dividend yield of 0% for all years; expected volatility of 61.7%; risk-free interest rates of 1.6%; and expected life of six years.
| b) | The total unrecognized compensation cost of employee stock options and restricted stock at December 31, 2016 is approximately $509,000. The unrecognized compensation cost of employee stock options is expected to be recognized over a weighted average period of 0.8 years.
The total cash received from employees as a result of employee stock option exercises for the years ended December 31, 2014, 2015 and 2016 was approximately $46,000, $534,000 and $14,000, respectively. The Company did not realize any tax benefit in connection with these exercises. During 2016, the Company issued 479,110 shares of Common Stock in connection with the exercise of 553,125 options granted to a certain employee of the Company. The Company received cash proceeds equal to approximately $14,000 in connection with such exercises.
| 2. | Options granted to consultants, directors, and other service providers:
On July 24, 2014, the Company’s Board of Directors approved, subject to certain terms and conditions, the grant of a 10-year option to purchase 150,000 shares of Common Stock to its then newly elected chairman of the Board of Directors with an exercise price equal to $3.37 per share. The options vest over a three-year period; the first 50,000 shares vest on the first anniversary of the grant date and the remaining shares vest in eight equal quarterly increments over the subsequent two-year period. Vesting of the options is subject to acceleration in full upon a Corporate Transaction or a Change in Control, as those terms are defined in the Plan. The Company estimated the fair value of the options on the date of grant using the Black-Scholes option-pricing model to be approximately $193,000 based on the following weighted average assumptions: dividend yield of 0% for all years; expected volatility of 62%; risk-free interest rates of 1.9%; and expected life of six years. No cash was received from consultants as a result of consultant stock option exercises for the years ended December 31, 2014, 2015 and 2016. During 2015 and 2016, no shares of Common Stock were issued in connection with the exercise of options by consultants of the Company.
| 3. | A summary of share option plans, and related information, under all of the Company’s equity incentive plans for the years ended December 31, 2014, 2015 and 2016 are as follows:
| a. | Options granted to employees:
|  | Year ended December 31, |
|  | 2014 |  | 2015 |  | 2016 |
|  |  |  | Weighted |  |  |  | Weighted |  |  |  | Weighted |
|  | Number |  | average |  | Number |  | average |  | Number |  | average |
|  | of |  | exercise |  | of |  | exercise |  | of |  | exercise |
|  | options |  | price |  | options |  | price |  | options |  | price |
Outstanding at beginning of year |  |  | 5,153,898 |  | $ | 3.951 |  |  | 5,870,309 |  | $ | 3.770 |  |  | 6,952,293 |  | $ | 3.363 |
Changes during the year: |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Granted |  |  | 900,000 |  |  | 2.370 |  |  | 1,909,000 |  |  | 1.72 |  |  |  |  |  |  |
Forfeited and Expired |  |  | 44,201 |  |  | 6.833 |  |  | 277,016 |  |  | 5.395 |  |  | 1,514,957 |  |  | 3.748 |
Exercised (*) |  |  | 139,388 |  |  | 0.446 |  |  | 550,000 |  |  | 0.972 |  |  | 553,125 |  |  | 0.067 |
Outstanding at end of year |  |  | 5,870,309 |  | $ | 3.770 |  |  | 6,952,293 |  | $ | 3.363 |  |  | 4,884,211 |  | $ | 3.617 |
Exercisable at end of year |  |  | 4,905,559 |  | $ | 3.933 |  |  | 4,477,043 |  | $ | 4.182 |  |  | 3,498,492 |  | $ | 4.296 |
| (*) | The total intrinsic value of options exercised during the years ended December 31, 2014, 2015 and 2016, was approximately $447,000, $675,000 and $213,000, respectively.
| b. | Restricted stock granted to employees:
|  | Year ended December 31, |
|  | 2014 |  | 2015 |  | 2016 |
|  | Number of Restricted Shares |
Outstanding at beginning of year |  |  | 970,208 |  |  | 386,124 |  |  | 127,874 |
Changes during the year: |  |  |  |  |  |  |  |  |  |
Vested |  |  | 398,375 |  |  | 255,749 |  |  | 127,874 |
Forfeited |  |  | 185,709 |  |  | 2,501 |  |  |  |
Outstanding at end of year |  |  | 386,124 |  |  | 127,874 |  |  | - |
| c. | Options and restricted stocks granted to consultants, directors, and other service providers:
|  | Year ended December 31, |
|  | 2014 |  | 2015 |  | 2016 |
|  | Number |  |  |  | Number |  |  |  | Number |  |  |
|  | of |  | Weighted |  | of |  | Weighted |  | of |  | Weighted |
|  | options/ |  | average |  | options/ |  | average |  | options/ |  | average |
|  | restricted |  | exercise |  | restricted |  | exercise |  | restricted |  | exercise |
|  | stock |  | price |  | stock |  | price |  | stock |  | price |
Outstanding at beginning of Year |  |  | 912,425 |  | $ | 7.259 |  |  | 1,208,592 |  | $ | 6.136 |  |  | 637,209 |  | $ | 11.638 |
Changes during the year: |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Granted |  |  | 296,167 |  |  | 2.678 |  |  |  |  |  |  |  |  |  |  |  |  |
Expired |  |  |  |  |  |  |  |  | 466,883 |  |  | 0.001 |  |  | 429,209 |  |  | 15.748 |
Vested restricted stock |  |  |  |  |  |  |  |  | 104,500 |  |  |  |  |  |  |  |  |  |
Outstanding at end of year |  |  | 1,208,592 |  |  | 6.136 |  |  | 637,209 |  |  | 11.638 |  |  | 208,000 |  |  | 3.156 |
Exercisable at end of year |  |  | 912,425 |  | $ | 7.259 |  |  | 549,709 |  | $ | 12.954 |  |  | 170,500 |  | $ | 3.109 |
| d. | The following tables summarize information concerning outstanding and exercisable options and restricted stock as of December 31, 2016:
December 31, 2016 |
Options |  |  |
outstanding |  | Options exercisable |
|  | Number of |  | Weighted |  |  |  | Weighted |
|  | options |  | average |  |  |  | average |
|  | outstanding |  | remaining |  | Number of |  | remaining |
Exercise |  | at end of |  | contractual |  | options |  | contractual |
prices |  | year |  | life |  | exercisable |  | life |
$ | 0.001 |  |  | 8,000 |  |  | 0.86 |  |  | 8,000 |  |  | 0.86 |
$ | 1.720 |  |  | 1,784,279 |  |  | 8.22 |  |  | 792,310 |  |  | 8.22 |
$ | 2.350 |  |  | 40,000 |  |  | 1.81 |  |  | 40,000 |  |  | 1.81 |
$ | 2.370 |  |  | 900,000 |  |  | 7.74 |  |  | 506,250 |  |  | 7.74 |
$ | 2.650 |  |  | 212,682 |  |  | 2.15 |  |  | 212,682 |  |  | 2.15 |
$ | 3.020 |  |  | 50,000 |  |  | 1.10 |  |  | 50,000 |  |  | 1.10 |
$ | 3.370 |  |  | 150,000 |  |  | 7.56 |  |  | 112,500 |  |  | 7.56 |
$ | 5.000 |  |  | 1,009,250 |  |  | 1.10 |  |  | 1,009,250 |  |  | 1.10 |
$ | 6.900 |  |  | 710,000 |  |  | 3.15 |  |  | 710,000 |  |  | 3.15 |
$ | 7.550 |  |  | 160,000 |  |  | 3.65 |  |  | 160,000 |  |  | 3.65 |
$ | 9.660 |  |  | 68,000 |  |  | 3.83 |  |  | 68,000 |  |  | 3.83 |
|  |  |  | 5,092,211 |  |  |  |  |  | 3,668,992 |  |  |  |
| e. | The following table illustrates the effect of share-based compensation on the statement of operations:
|  | Year ended December 31, |
(U.S. dollars in thousands) |  | 2014 |  | 2015 |  | 2016 |
Research and development expenses |  | $ | 936 |  | $ | 904 |  | $ | 571 |
Marketing, general and administrative expenses |  |  | 306 |  |  | 898 |  |  | 417 |
|  | $ | 1,242 |  | $ | 1,802 |  | $ | 988 |
| c. | Private and 144A Offerings
| 1. | On October 12, 2015, the Company completed a private offering of 5,649,079 shares of the Company’s common stock to Pfizer. See also note 2.
| 2. | On December 7, 2016, the Company exchanged with certain existing noteholders $54.052 million aggregate principal amount of the Company’s outstanding 4.50% Convertible Senior Notes due 2018 for, among other consideration, $40.186 million aggregate principal amount of convertible notes due 2021 (as described in note 8b) and for 23,846,735 shares of common stock. See also note 8b.

X
- References No definition available. + Details
Name: | us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 310 -SubTopic 10 -Section S99 -Paragraph 4 -Subparagraph (SAB Topic 4.E) -URI http://asc.fasb.org/extlink&oid=27010918&loc=d3e74567-122707 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 4 -URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21484-112644 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 5 -URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21488-112644 Reference 5: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 235 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(e)) -URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690 Reference 6: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(31)) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 Reference 7: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section S99 -Paragraph 4 -Subparagraph (SAB Topic 4.C) -URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187143-122770 Reference 8: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 Reference 9: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 6 -URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21506-112644 Reference 10: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 235 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(d)) -URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690 Reference 11: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770 Reference 12: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 30 -Section 50 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=6405834&loc=d3e23285-112656 Reference 13: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 3 -URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21475-112644 Reference 14: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Glossary Preferred Stock -URI http://asc.fasb.org/extlink&oid=6521494 Reference 15: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644 Reference 16: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 11 -URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21564-112644 + Details
Name: | us-gaap_StockholdersEquityNoteDisclosureTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration